Shorter durations of venetoclax yields similar response rates in AML

Elbert Kuo joins Baptist MD Anderson to lead the Division of Surgery

Elbert Y. Kuo, a thoracic surgeon who specializes in minimally invasive techniques, has joined Baptist MD Anderson Cancer Center as head of the Division of Surgery and surgeon-in-chief.

July 18, 2025

Vol.51 No.28

Clinical Roundup

Nivolumab + relatlimab improve survival in advanced melanoma, MD Anderson study shows

Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87% of patients with stage 3 melanoma remained alive, according to new results from a study led by researchers at the University of Texas MD Anderson Cancer Center.

July 18, 2025

Vol.51 No.28

Clinical

How MD Anderson and Texas Children’s made plans to build a $1 billion pediatric cancer hospital—one of the world’s largest

The windows down the hall from the operating room scrub sinks at MD Anderson Cancer Center look out at the tower of Texas Children’s Hospital.

Multi-institutional team awarded $3.4M NCI grant to open AML trial

The University of Cincinnati Cancer Center, The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and Jabez Biosciences are partnering to open a new phase I clinical trial studying JBZ-001, a potential new treatment for acute myeloid leukemia.

June 27, 2025

Vol.51 No.25

Clinical Trials & Tribulations

Optimizing dosing of expensive and toxic oncology drugs: Making America healthier

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals. But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half. Simply stated, cost is the product of (price per unit times the number of units purchased).

June 20, 2025

Vol.51 No.24

By Mark J. Ratain, David A. Hyman, Jill E. Feldman, Beth R. Jacobson and Allen S. Lichter

Clinical Roundup

Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T-cell therapy

In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center identified three subgroups of patients with large B-cell lymphoma who have different levels of benefit from CD19 chimeric antigen receptor T cell therapy.

June 20, 2025

Vol.51 No.24

Shorter durations of venetoclax yields similar response rates in AML

YOU MAY BE INTERESTED IN

Elbert Kuo joins Baptist MD Anderson to lead the Division of Surgery

Nivolumab + relatlimab improve survival in advanced melanoma, MD Anderson study shows

How MD Anderson and Texas Children’s made plans to build a $1 billion pediatric cancer hospital—one of the world’s largest

Multi-institutional team awarded $3.4M NCI grant to open AML trial

Optimizing dosing of expensive and toxic oncology drugs: Making America healthier

Researchers identify key B-cell lymphoma traits linked with greatest benefit from CD19 CAR T-cell therapy

Renew today!

Subscriber content

Never miss an issue!

Login